Organon & Co.
OGNHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Organon & Co. focuses on Drug Manufacturers - General services and products. Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle. The company carries a $3.55B market cap, placing it firmly in the mid-cap category. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis.
Market Cap
$3.55B
Beta
1.54
P/E (TTM)
14.54
P/E (Fwd)
3.72
EPS (TTM)
$0.93
EPS (Fwd)
$3.64
ROE
34.1%
ROA
5.9%
Cash
$1.12B
Total Debt
$8.57B
Free CF
$529.1M
52W Change
42.9%
Annual Financials
Cash vs Debt
Organon & Co. carries $8.57B in total debt against $1.12B in cash reserves — debt is roughly 7.7x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $529.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 34.1%, which is exceptionally high for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 5.9% suggests reasonable efficiency in deploying the company's asset base. Revenue has been relatively flat, moving from $6.17B (2022) to $6.22B (2025).
With a beta above 1.5, OGN tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing OGN.